Also known as: U.S. federal cannabis prohibition · Controlled Substances Act and cannabis · DEA cannabis scheduling

Federal Cannabis Law in the United States

How federal prohibition coexists with state legalization, and what may change.

Automated fact-check pass

10 cited sources

Published May 31, 2026

Last reviewed Oct 31, 2026

This article is general information, not legal advice. Laws change; check current rules with official sources or a lawyer.

↯ The honest take

Federal law still treats cannabis as a Schedule I drug with no accepted medical use, even though 24 states and D.C. allow adult use and 38 have medical programs. State legality does not override federal prohibition; what changed is enforcement priority and hemp's legal status. A 2024 proposal to move cannabis to Schedule III is not yet final. Full legalization requires Congress.

The Controlled Substances Act and Schedule I status

Cannabis was placed in Schedule I of the Controlled Substances Act (CSA, enacted in 1970) as a drug with high abuse potential and no accepted medical use ^[1]. Strong evidence Schedule I status means cannabis is treated as more tightly restricted than drugs in Schedules II–V, which include prescription opioids, stimulants, and depressants.

Schedule I status has consequences far beyond criminal penalties. It severely restricts research access, blocks cannabis businesses from normal banking services, prevents them from claiming ordinary business tax deductions under IRC § 280E, and makes cannabis use grounds for deportation or inadmissibility of non-citizens ^[2] Strong evidence. Simple possession of any amount is a federal misdemeanor for a first offense, though federal prosecutors rarely pursue small possession cases in practice.

State legalization vs. federal prohibition

As of October 2026, 24 states plus Washington, D.C. have legalized adult-use (recreational) cannabis, and 38 states have medical cannabis programs ^[3]. None of this changes federal law. Under the Supremacy Clause, federal law preempts state law, and the Supreme Court affirmed in Gonzales v. Raich (2005) that Congress has authority to criminalize cannabis even when grown and consumed entirely within a state that permits it Strong evidence.

What has changed is enforcement discretion. Since 2014, Congress has annually passed the Rohrabacher–Farr amendment (renamed the Joyce amendment after Rep. Greg Joyce in 2023), which forbids the Department of Justice from spending appropriated funds to prosecute people complying with state medical cannabis laws ^[4] Strong evidence. This protection applies only to medical, not adult-use, programs; must be renewed each year as part of the federal budget; and does not change cannabis's underlying Schedule I status.

The earlier Cole Memorandum (2013) set DOJ enforcement priorities deferring to well-regulated state cannabis markets. Attorney General Jeff Sessions rescinded it in 2018. However, in practice, federal prosecutors have continued to focus on interstate trafficking, sales to minors, and links to organized crime rather than state-compliant operators ^[5].

Hemp and the 2018 Farm Bill

The Agriculture Improvement Act of 2018 ("2018 Farm Bill") removed hemp from the CSA entirely ^[6] Strong evidence. Hemp is defined as cannabis containing no more than 0.3% delta-9 THC by dry weight. This created the legal framework for hemp-derived cannabinoids sold outside state cannabis programs, including CBD, delta-8 THC, HHC, and THCA products.

The FDA retains regulatory authority over hemp-derived ingredients in food, drugs, and supplements. The agency has stated that CBD cannot be lawfully added to food or sold as a dietary supplement under current rules ^[7] Strong evidence. Hemp-derived intoxicating compounds like delta-8 and HHC occupy a legal gray zone the 2018 Farm Bill drafters did not anticipate. Several states have banned or restricted these products independently, creating a patchwork of state regulations overlaid on federal ambiguity.

The 2024 rescheduling proposal

In August 2023, the Department of Health and Human Services recommended that the DEA move cannabis from Schedule I to Schedule III. In May 2024, the DOJ formally published a Notice of Proposed Rulemaking to implement that recommendation ^[8] Strong evidence. As of October 2026, the rulemaking is not final. It must complete the public comment period and administrative hearing process before taking effect.

If finalized, Schedule III status would:

Eliminate the IRC § 280E tax penalty for state-legal cannabis businesses
Significantly ease federal research restrictions
Formally acknowledge accepted medical use

It would not:

Legalize state adult-use programs under federal law (recreational sale would still violate the CSA)
Permit interstate commerce in cannabis
Resolve banking, immigration, or firearms collateral consequences automatically

Rescheduling is a meaningful but partial change. Full federal legalization would require an act of Congress.

Collateral federal consequences

Even where state law permits cannabis use, federal status creates downstream problems:

Firearms. ATF Form 4473 requires gun buyers to certify they are not unlawful users of a controlled substance. Cannabis users — even medical patients in legal states — must answer "yes" and are federally prohibited from purchasing firearms (18 U.S.C. § 922(g)(3)) Strong evidence. Post-Bruen, the constitutionality of this firearms ban is being litigated; an appellate court ruled it unconstitutional in 2023, though the issue remains contested ^[9] Disputed.

Immigration. Cannabis use, admission of use, or working in the legal cannabis industry can render non-citizens inadmissible or deportable. USCIS has explicitly confirmed this applies even to state-legal conduct ^[2] Strong evidence. For details, see Federal Immigration Consequences of Cannabis.

Federal employment and security clearances. Federal agencies historically disqualified cannabis users. Policies have begun to shift: some agencies now consider only disqualifying conduct (e.g., dishonesty about use) rather than use itself, particularly for past or casual use. However, no uniform federal standard exists; practices vary by agency and clearance level Weak / limited.

Banking. Most federally chartered banks decline cannabis-business accounts due to money-laundering compliance concerns. The SAFE Banking Act has passed the House multiple times but has not become law ^[10] Strong evidence. See Federal Cannabis Banking Restrictions for details.

Interstate travel. Carrying cannabis across state lines — even between two legal states — is federal trafficking under the CSA. TSA's stated policy is to refer suspected cannabis to local law enforcement Strong evidence.

Not legal advice

This article is not legal advice. Federal cannabis law changes frequently and applies differently depending on your state, immigration status, security clearance eligibility, employment, specific conduct, and local law. If you face a legal decision involving cannabis — including employment, firearm purchase, immigration status, or criminal charges — consult a licensed attorney in your jurisdiction.

Sources

How this page was made

Generation history

Oct 31, 2026

Fact-check pass — raised 10 flags

Oct 31, 2026

Revision

May 31, 2026

Initial draft